Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

OBJECTIVES: To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to conventional synthetic DMARDs (csDMARD-IR). MET...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Desirée, Schiff, Michael, Tanaka, Yoshiya, Xie, Li, Meszaros, Gabriella, Ishii, Taeko, Casillas, Marta, Ortmann, Robert A, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525612/
https://www.ncbi.nlm.nih.gov/pubmed/31168413
http://dx.doi.org/10.1136/rmdopen-2019-000898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525612/
https://www.ncbi.nlm.nih.gov/pubmed/31168413
http://dx.doi.org/10.1136/rmdopen-2019-000898

Ejemplares similares